GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Book Value per Share

Ascentage Pharma Group International (HKSE:06855) Book Value per Share : HK$2.62 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Book Value per Share?

Ascentage Pharma Group International's book value per share for the quarter that ended in Jun. 2024 was HK$2.62.

During the past 12 months, Ascentage Pharma Group International's average Book Value Per Share Growth Rate was 17.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -62.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Ascentage Pharma Group International was -28.70% per year. The lowest was -62.80% per year. And the median was -45.75% per year.

Ascentage Pharma Group International's current price is HK$37.15. Its book value per share for the quarter that ended in Jun. 2024 was HK$2.62. Hence, today's PB Ratio of Ascentage Pharma Group International is 162.94.

During the past 9 years, the highest P/B Ratio of Ascentage Pharma Group International was 209.21. The lowest was 1.99. And the median was 9.68.

Good Sign:

Ascentage Pharma Group International stock PB Ratio (=41.12) is close to 1-year low of 41.12.


Ascentage Pharma Group International Book Value per Share Historical Data

The historical data trend for Ascentage Pharma Group International's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Book Value per Share Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Book Value per Share
Get a 7-Day Free Trial Premium Member Only 4.44 5.75 1.72 0.23 0.90

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 2.23 0.23 2.62 0.90

Competitive Comparison of Ascentage Pharma Group International's Book Value per Share

For the Biotechnology subindustry, Ascentage Pharma Group International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's PB Ratio falls into.


;
;

Ascentage Pharma Group International Book Value per Share Calculation

Ascentage Pharma Group International's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(66-0)/290
=0.23

Ascentage Pharma Group International's Book Value Per Share for the quarter that ended in Jun. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(825-0)/315
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Ascentage Pharma Group International  (HKSE:06855) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Ascentage Pharma Group International Book Value per Share Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Takeda Pharmaceuticals International Ag 2101 Beneficial owner
Takeda Pharmaceuticals Company Limited 2201 Interest of corporation controlled by you
Gao Sharon Xia
Zhai Yifan
Yang Dajun
Wang Shaomeng
Li Ju-yun
Healthquest Pharma Limited
Guo Edward Ming
Ascentage Limited
South Dakota Trust Company Llc 2301 Trustee
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines